Chromosome Instability May Be Prognostic in Non–Small-Cell Lung Cancer

Intratumor heterogeneity is associated with an increased risk for disease recurrence or death.

The use of intratumor heterogeneity and clonal evolution to predict clinical outcomes in patients with early-stage non–small-cell lung cancer (NSCLC) has had limited exploration in large prospective studies. To determine the prognostic value of these factors, investigators conducted a prospective, multicenter, cohort study (TRACERx) in which whole-exome sequencing was performed on 327 regions of 100 resected NSCLC tumors.

Results were as follows:

Extensive intratumor heterogeneity was present; a median 30% of somatic mutations were subclonal, and a median 48% of copy-number alterations were subclonal.
There was wide variation between tumors, with a range of 2 to 2310 subclonal mutations and a range of 0.06% to 81% tumor involvement by subclona…

Reviewing Author

Anne S. Tsao, MD

Disclosures

Consultant/Advisory BoardGenentech; AstraZeneca; Boehringer-Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Heron; Takeda; Ariad; MedIQ; Targeted Healthcare Communications; Novartis; OncLive; Roche; TRM Oncology

RoyaltiesUpToDate

Grant/Research SupportMedimmune; NIH/National Cancer Institute; Millennium; Genentech; Polaris Pharmaceuticals; Seattle Genetics; Boehringer-Ingelheim Pharmaceuticals; SWOG–Hope Foundation; American Cancer Society; Department of Defense; GlaxoSmithKline Pharmaceuticals; Merck; Eli Lilly; Takeda; Bristol-Myers Squibb

Anne S. Tsao, MD

Disclosures

RoyaltiesUpToDate

Chromosome Instability May Be Prognostic in Non–Small-Cell Lung Cancer

Topics

Reviewing Author